{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-015550","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.223789+00:00","generated_at":"2026-06-18T22:47:58.585999+00:00","sec_items":["1.01","3.02","3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Allarity Therapeutics raises $1.2M via Series C Convertible Redeemable Preferred Stock offering","bullets":["Sold 50,000 shares of Series C Preferred at $24/share for $1.2M total to an accredited investor.","Series C carries 5% annual dividend, convertible at lower of $0.182 or market price, floor $0.037.","Redemption at 110% of stated value ($27) after 60 days up to 365 days from issue.","Special meeting on March 20, 2023 to seek stockholder approval for authorized share increase and reverse stock split.","Registration rights agreement requires filing; failure triggers 2% monthly liquidated damages on subscription amount."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-015550","json":"https://secwatch.observer/filing/0001213900-23-015550.json","markdown":"https://secwatch.observer/filing/0001213900-23-015550.md","text":"https://secwatch.observer/filing/0001213900-23-015550.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023015550/0001213900-23-015550-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023015550/ea174273-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:47:58.585999+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0de9986950c520aacaa3f473b82616a7df99764d","claim":"Allarity Therapeutics, Inc.: Filed Certificate of Designation of Series C Preferred Stock (effective 2023-02-24).","evidence_excerpt":"Pursuant to the terms of the SPA, on February 24, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series C Preferred Stock (the “Series C COD”) with the Delaware Secretary of State designating 50,000 shares of its authorized and unissued preferred stock as Series C Preferred Stock with a stated value of $27.00 per share (the “Stated Value”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023015550/0001213900-23-015550-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-02-24"}],"fact_type":"governance_change"},{"claim_id":"275438e4d99e8a1ba4ede587ddc36a1410bcb3e5","claim":"Allarity Therapeutics, Inc.: Filed certificate of amendment to Series C COD to clarify conversion price and floor price (effective 2023-02-28).","evidence_excerpt":"On February 28, 2023, the Company filed a certificate of amendment to the Series C COD (the “COD Amendment”) to clarify the terms of conversion price and floor price based on definitions provided in the Series C COD","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023015550/0001213900-23-015550-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-02-28"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}